24/7 Market News Snapshot 10 July, 2025 – PainReform Ltd. Ordinary Shares (NASDAQ:PRFX)

July 10, 2025

DENVER, Colo., 10 July, 2025 (www.247marketnews.com) – (Nasdaq:PRFX) are discussed in this article.
PainReform Ltd. (Nasdaq:PRFX) is currently facing a downward trading trend, with shares falling to $1.321 in pre-market activity, a decline of 4.28% from the prior close of $1.380. This downturn has been accompanied by heightened trading volume, peaking at 2.15 million shares, indicating increased market activity that could impact future price movements. Investors are advised to monitor key support levels near $1.30 and resistance points around $1.38, as these could guide expectations for the stock’s short-term trajectory.

In a strategic move, PainReform has entered into a pivotal investment agreement with LayerBio Inc., a forward-thinking biotechnology firm recognized for its groundbreaking non-opiate treatments aimed at improving patient outcomes in ophthalmic surgery. This partnership marks PainReform’s initiative to expand its pharmaceutical offerings, particularly in ophthalmology, by adopting an innovative drug delivery platform aligned with its mission for effective non-opiate pain management.

Under the terms of the agreement, PainReform will acquire a majority equity stake in LayerBio and secure a dominant position on its board of directors. The financial structure of this partnership involves an initial investment of $600,000 upon closure, with additional capital reaching a total of $3 million contingent on the successful completion of designated development milestones. These funds will primarily support LayerBio’s anticipated Phase II clinical trial for OcuRing™-K, a cutting-edge sustained-release intraocular ring designed to deliver critical anti-inflammatory and analgesic medications post-cataract surgery.

Dr. Ehud Geller, Chairman and interim CEO of PainReform, highlighted the importance of this collaboration, emphasizing that the partnership with LayerBio positions the company to enter the ophthalmology sector with a differentiated solution for a significant clinical need. Meanwhile, Dr. Ken Mandell, LayerBio’s CEO, will continue leading the company, drawing from his extensive expertise in sustained-release drug delivery systems. Through these developments, PainReform reaffirms its commitment to creating long-acting, non-opiate therapeutic options that enhance recovery while aiming to mitigate opioid dependency in medical settings.

Related news for (PRFX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.